Evidence map›Paper›PMID 28382709›Full record

ArticleJournal of peptide science : an official publication of the European Peptide Society2017

Computational prediction of the optimal oligomeric state for membrane-inserted β-barrels of protegrin-1 and related mutants.

Richard Lipkin, Themis Lazaridis

Abstract read
In one paragraph

Article in Journal of peptide science : an official publication of the European Peptide Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Richard LipkinDepartment of Chemistry, City College of New York, 160 Convent Ave., New York, NY, 10031, USA.
Themis LazaridisDepartment of Chemistry, City College of New York, 160 Convent Ave., New York, NY, 10031, USA.ORCID http://orcid.org/0000-0003-4218-7590

Funding

Cellular/Molecular Basis of Development: Research CenterG12MD007603 · NIMHD · CITY COLLEGE OF NEW YORK · PI PEZZANO, MARK · 2012 to 2017
$11.5M
Mechanism of membrane pore formation by antimicrobial peptidesR01GM117146 · NIGMS · CITY COLLEGE OF NEW YORK · PI LAZARIDIS, THEMIS · 2016 to 2019
$1.2M
NIGMS NIH HHS R01 GM117146NIMHD NIH HHS G12 MD007603
6 · The paper itself

Abstract

Protegrin-1 is a widely studied 18-residue β-hairpin antimicrobial peptide. Evidence suggests that it acts via a β-barrel pore formation mechanism, but the exact number of peptides comprising the pore state is unknown. In this study, we performed molecular dynamics simulations of β-barrels of protegrin and three related mutants (v14v16l, v14v16a, and r4n) in NCNC parallel topology in implicit membrane pores of varying radius and curvature for oligomeric numbers 6-14. We then identified the optimal pore radius and curvature values for all constructs and determined the total effective energy and the translational and rotational entropic losses. These, along with an estimate of membrane deformation free energy from experimental line tension values, provided an estimate of the overall energetics of formation of each pore state. The results indicated that oligomeric numbers 7-13 are generally stable, allowing the possibility of a heterogeneous pore state. The optimal oligomeric state for protegrin is the nonamer, shifting to higher numbers for the mutants. Protegrin, v14v16l, and r4n are stable as membrane-inserted β-barrels, but v14v16a seems much less so because of its decreased hydrophobicity. Copyright © 2017 European Peptide Society and John Wiley & Sons, Ltd.

Indexed as

Molecular Dynamics SimulationAntimicrobial Cationic PeptidesAntimicrobial Cationic Peptidesprotegrin-1antimicrobial peptideseffective energy function 1implicit membrane model 1molecular dynamicsprotegrin-1β-barrel

Identifiers

PMID28382709
PMCPMC5689075

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.